Internally standardized method for the determination of nalbuphine in human plasma by means of high performance liquid chromatography with electrochemical coulometric detection.

A high performance liquid chromatographic method with internal analogue standardization and electrochemical detection for the determination of nalbuphine in human plasma is described. Using 3 ml plasma the lower limit of detection is below 50 pg/ml, during the routine assay the limit of determination can be fixed at about 250-300 pg/ml. The calibration curve is linear in the range between 0.

High-pressure liquid chromatographic method for the determination of hydromorphone in human plasma with electrochemical detection.

A high-pressure liquid chromatographic method with internal analogue standardization for the determination of hydromorphone (Dilaudid) in human plasma is described. The method involves extraction from plasma with chloroform and quantification with an electrochemical detector after high-pressure liquid chromatographic separation on an ion-pair column. Using 3 ml plasma the detection limit is about 50 pg/ml; in the routine procedure the limit of determination can be fixed at about 250 pg/ml with a correlation coefficient of about 10%.

[Human pharmacokinetics of theophylline and etofylline from different formulations of a cardiotonic (author's transl)].

Serum concentrations of theophylline and etofylline were analysed by a specific HPLC-method in 6 volunteers after i.v. and p.

[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic].

Upon investigations on metabolism and pharmacokinetics of 1-(theophyllin-7-yl)-ethyl-2-[2-(chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, ML 1024, Duolip) is reported. As can be seen from in vivo tests in rats and dogs ML 1024 is cleaved to the metabolites clofibric acid and etofylline. This could be further demonstrated in vitro by incubation with lipases and human serum.

[Relative bioavailability of a new spironolactone preparation (author's transl)].

The investigations have been performed to determine the relative bioavailability of canrenon from Acelat 100 capsules in comparison with canrenon from a spironolactone standard preparation available on the German market. This was carried out by comparing the areas under the serum fluctuation curves after oral application of both preparations as well as by urine excretion extrapolated infinitely. The preparations were administered together with a standard breakfast.